FUNDAMENTALS
EdgeFII/DII
AUROPHARMAAurobindo Pharma
₹1,799.00-0.37%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
AUROPHARMANSE · EquityPharmaceuticals

Aurobindo Pharma

ISIN
INE406A01037
Instrument key
NSE_EQ|INE406A01037
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹1,799.00-6.70 · -0.37%
Day rangecircuit ₹1,619.10 – ₹1,978.90
1,788.10
1,817.50

as of 21/11/2026, 2:24:15 pm

Open
₹1,788.10
Day high
₹1,817.50
Day low
₹1,788.10
Prev. close
₹1,805.70
Volume
8.11 L
VWAP
₹1,804.42

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 day · 5-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M
6M
1Y
5Y
MAX

No candles for this range

Intraday candles are empty outside market hours — pick a longer range.

Candle data0 rows of open, high, low, close and volumeShowHide

No candles in this range

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

25.91
Company
25.91
Sector
-45.02

Worse than sector by 158%

P/B

Price ÷ book value per share

2.62
Company
2.62
Sector
4.21

Better than sector by 38%

ROA

Net income ÷ total assets

6.46%
Company
6.46%
Sector
1.19%

Better than sector by 443%

ROE

Net income ÷ shareholders' equity

10.13%
Company
10.13%
Sector
-0.4%

Better than sector by 2633%

ROCE

EBIT ÷ capital employed

12.76%
Company
12.76%
Sector
15.44%

Worse than sector by 17%

Quick Ratio

Liquid assets ÷ current liabilities

1.15
Company
1.15
Sector
4.8

Worse than sector by 76%

EV/EBITDA

Enterprise value ÷ EBITDA

12.53
Company
12.53
Sector
22.86

Better than sector by 45%

04/Business

About the company

Sector: Pharmaceuticals

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.

Sector market cap (INR)
₹1,03,298 Cr

reported in crore

Sector market cap (USD)
$11.48B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹34,145 Cr
+5.56% vs Mar 2025
Net profit · Mar 2026
₹3,503 Cr
+0.56% vs Mar 2025
Operating margin
15.0%
was 15.7%
Revenue CAGR · 4p
10.7%
profit 22.0% · op 25.1%
Filed order
Revenue34,14532,34629,55925,146
Revenue growthreported5.6%9.4%17.6%—
Operating profit5,1125,0664,3802,613
Operating profit growthreported0.9%15.7%67.7%—
Operating marginderived15.0%15.7%14.8%10.4%
Net profit3,5033,4843,1691,928
Net profit growthreported0.6%9.9%64.4%—
Net marginderived10.3%10.8%10.7%7.7%
EPS — basic₹/share, annual60.3459.8154.1632.90

Figures in ₹ crore. Margin rows are computed from the reported values.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹58,502 Cr
+17.51% YoY
Total liabilities
₹20,619 Cr
Net worth
₹37,883 Cr
Liabilities ÷ assets
35.2%
lower means a lighter balance sheet
Filed order
Total assets58,50249,78545,07239,890
Total liabilities20,61917,13815,22113,038
Net worthderived37,88332,64729,85126,852
Liabilities ÷ assetsderived35.2%34.4%33.8%32.7%
Asset growthderived17.5%10.5%13.0%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets25,79322,62321,30018,430
Current Assets32,70927,16223,77221,460
Total Assets58,50249,78545,07239,890
Current Liabilities18,03914,68212,19911,494
Net Current Asset14,67012,48011,5739,966
Non-Current Liabilities2,5802,4563,0221,544
Equity Capital37,88332,64729,85126,852
Total Equity & Liabilities58,50249,78545,07239,890

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹5,526 Cr
+40.81% YoY
Investing
-₹3,459 Cr
Financing
-₹1,269 Cr
Free cash flow
₹2,068 Cr
operating + investing
Filed order
Operating activities5,5263,9252,4352,387
Operating changereported40.8%61.2%2.0%—
Investing activities-3,459-1,876-4,256-3,978
Investing changereported-84.4%55.9%-7.0%—
Financing activities-1,2691208001,814
Financing changereported-1159.6%-85.0%-55.9%—
Net cash flowderived7992,169-1,021223
Free cash flowoperating + investing2,0682,049-1,821-1,591

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax5,1125,0664,3802,613
Income before WC changes7,1946,9005,8764,199
Change in Assets-2,935-1,598-2,410-1,933
Change in Liabilities3,099353735838
Change in WC164-1,244-1,675-1,095
Cash flow from Operations5,5263,9252,4352,387
Cash flow from Investing-3,459-1,876-4,256-3,978
Cash flow from Financing-1,2691208001,814
Total Cash Flow7992,169-1,021223
Cash (Start of the year)5,5643,3854,3924,163
Cash (End of the year)7,1915,5643,3854,392

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
51.88%
0.00 pts QoQ
FII
17.41%
+1.03 pts QoQ
DII (other)
8.11%
-0.28 pts QoQ
Mutual funds
16.31%
-0.40 pts QoQ
Retail & others
6.29%
-0.35 pts QoQ
Filed order
Promoters51.9%51.9%51.8%51.8%
FII17.4%16.4%15.2%13.9%
DII (other)8.1%8.4%8.1%8.2%
Mutual funds16.3%16.7%17.8%19.5%
Retail & others6.3%6.6%7.1%6.5%
Promoters — QoQ changepts, derived0.0%0.1%0.0%—
FII — QoQ changepts, derived1.0%1.1%1.3%—
DII (other) — QoQ changepts, derived-0.3%0.3%-0.1%—
Mutual funds — QoQ changepts, derived-0.4%-1.1%-1.7%—
Retail & others — QoQ changepts, derived-0.3%-0.4%0.5%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendInterim₹7.00700.0%11 Nov 202611 Nov 202604 Nov 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.

Full annual line itemsRevenue, other income, expenses, tax, EPS
ShowHide
Filed order
Revenue33,65331,72429,00224,855
Other Income492622557291
Total Revenue34,14532,34629,55925,146
Total Expenses28,97027,24824,97022,522
Profit Before Tax5,1125,0664,3802,613
Tax1,6091,5831,211685
Profit After Tax3,5033,4843,1691,928
EPS - Basic60.3459.8154.1632.90
EPS - Diluted60.3459.8154.1632.90

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.